“The expanded indication for DEFINITY is a testament to the rigorous research and development efforts undertaken by Lantheus to address unmet medical needs of pediatric patients,” said Jean-Claude ...
N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...
NORTH BILLERICA, Mass.-- (BUSINESS WIRE)-- Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback